Certolizumab pegol, a pegylated anti-TNF-α antagonist, caused de novo-onset palmoplantar pustulosis followed by generalized pustular psoriasis in a patient with rheumatoid arthritis.
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Haruka
H
Koizumi
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Atsushi
A
Tokuriki
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Noritaka
N
Oyama
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Hideki
H
Ido
Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Kazumitsu
K
Sugiura
Department of Dermatology, Nagoya University Graduate School of Medicine, Aichi, Japan.
Masashi
M
Akiyama
Department of Dermatology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Minoru
M
Hasegawa
D000284:Administration, Oral; D000368:Aged; D018501:Antirheumatic Agents / Q000009:adverse effects*; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology; D000068582:Certolizumab Pegol / Q000009:adverse effects*; D018450:Disease Progression; D005050:Etretinate / Q000008:administration & dosage; D005260:Female; D005528:Foot; D006225:Hand; D006801:Humans; D007641:Keratolytic Agents / Q000008:administration & dosage; D011565:Psoriasis / Q000139:chemically induced* / Q000188:drug therapy / Q000276:immunology / Q000473:pathology; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors / Q000276:immunology
D018501:Antirheumatic Agents; D007641:Keratolytic Agents; C439524:TNF protein, human; D014409:Tumor Necrosis Factor-alpha; D005050:Etretinate; D000068582:Certolizumab Pegol